Our Mission
Change the world, one protein at a time.
## Company Fast Facts

<table>
<thead>
<tr>
<th>Year</th>
<th>Founded</th>
<th>Founder</th>
<th>Headquarters</th>
<th>Total employees</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>Sean McClain</td>
<td>Vancouver, WA</td>
<td>170+</td>
<td></td>
</tr>
</tbody>
</table>

Total investment to date: $230M
- Closed a **$125 million in crossover financing** in March 2021
- The crossover was co-led by existing investors Casdin Capital and Redmile Group, with participation from new investors Fidelity Management and Research Company LLC, D1 Capital Partners, Perceptive Advisors, aMoon Edge, and Irving Investors, as well as other existing investors including ArrowMark Partners.
- In February 2021, announced a **strategic equity investment** by Merck Global Health Innovation Fund (Merck GHI) and potential discovery collaborations with Merck Research Laboratories.
- Closed a **$65 million Series E round** in October 2020
Key Acquisitions To Date

**TOTIENT**

**Totient (June 2021)**
The development of comprehensive predictive models that encompass the interactions of key proteins related to immune responses in different disease states is an enormous opportunity for biologic drug development. Building on Totient’s ability to identify fully-human antibodies from patients who demonstrate differentiated immune responses, Absci expects to generate a large collection of natural human antibodies and target antigens that it may leverage for therapeutic protein design as well as deep learning model training.

**DENOVVUM**

**Denovium (January 2021)**
The Denovium Engine is a multidimensional deep learning model built to interpret, categorize, predict, and evolve function and behavior of proteins. The platform incorporates far more than sequence and structure relationships, having been trained on functional data from more than 100 million proteins and across over 700,000 descriptive parameters. Absci intends to further train the Denovium Engine on its proprietary internally-generated multidimensional protein characterization datasets that include elements of protein functionality, expression, and manufacturability.
Absci is a pioneering synthetic biology company.

Our AI-powered platform for protein discovery and production enables pharma companies to create drugs that are impossible to make with current technologies and bring life-saving medicines to patients faster and more efficiently.

The AI-powered platform accelerates preclinical development, enabling partners to get new treatments to patients faster, including those diagnosed with complex diseases like cancers and autoimmune disorders.
Our Integrated Drug Creation™ Platform

Our platform enables the creation of next-generation therapeutics by unifying biologic drug discovery and cell line development into a seamless process. Absci marries synthetic biology technologies and deep learning to predict, design, construct, screen, select, and scale up novel drug candidates. Current approaches generally rely on finding something nature has already created, or reconfiguring parts into a new (and often nonfunctional) format. Absci’s AI models search the universe of potential sequences, and proprietary *E. coli* strains create custom-designed proteins specific to their intended target.

Think of Absci as Google Search for drug discovery. Our AI-powered predictive abilities become more accurate and efficient over time -- so instead of scrolling through multiple pages of search results, you get the information you need first. The more we use these models, the more data they ingest, and the better they get at predicting which drug candidates will work for a specific disease.

Our Partners

Absci partners with the most prominent pharma companies, including **Merck** and Astellas, with the aim to discover new protein-based drugs (biologics), achieve previously impossible production scales, expand preclinical pipelines, and accelerate time-to-patient by creating novel biologics at unprecedented speeds. Our technology truncates preclinical timelines from years to months to weeks. We currently have nine active programs spanning seven partnerships.
Our Story

Sean McClain founded Absci in 2011 with the vision to upend traditional biomanufacturing, accelerating development and reducing manufacturing costs. Sean, who developed a passion for synthetic biology while studying at the University of Arizona, started the company in a basement lab at just 22 years old. With Genentech’s insulin as inspiration, Sean set out to identify a more efficient way to manufacture proteins in *E. coli*.

Today, our founder-led team lives by the mantra: “believe in the impossible.” We are disrupting the pharmaceutical industry with bold ideas and fulfilling the promise of life-saving medicines for patients by Translating Ideas into Drugs™. Each of our team members -- leading experts in the scientific, AI, engineering, and pharma communities -- brings their energy, expertise, and enthusiasm as we pursue the shared inspiration to chart a new path to better biologics.

Power of Proteins

Proteins have the potential to treat diseases that we can’t yet cure and greatly improve human health. Protein-based drugs, or biologics, have already transformed vaccine development, oncology therapies, and treatments for chronic diseases like diabetes -- but these breakthroughs only scratch the surface of what’s possible. The next generation of biologics will be able to treat the most complex diseases, like neurologic and autoimmune disorders, in highly targeted, and even personalized ways.

Proteins have limitless potential and can be designed to be exquisitely specific. This “superpower” has the ability to transform how we treat diseases -- treatments that were historically challenging to discover, time-consuming to develop, and expensive (or even impossible) to manufacture.
Executive Bio - Sean McClain

Sean McClain, founder and CEO of Absci, started the company in 2011 with a bold vision to unify biologic drug discovery and development processes, taking a synthetic biology approach and working with the industry’s original biomanufacturing organism, *E. coli*. Driven by the mantra “believe in the impossible” and pursuing a mission to change the world, one protein at a time, he has built a leading synthetic biology company that is merging artificial intelligence with protein-based drug discovery to step beyond nature’s boundaries with a revolutionary new approach to biopharmaceutical development.

Under Sean’s leadership, Absci has grown to more than 170 employees, raised $230M, acquired target discovery company Totient and deep learning company Denovium, and established partnerships with industry-leading pharmaceutical and biotech companies including Merck and Astellas. Sean, who studied biochemistry and molecular biology at the University of Arizona, has been recognized as part of the 2019 Forbes 30 Under 30 cohort in Science, named as an Entrepreneur of The Year 2020 Pacific Northwest Region Award Winner, and included among the 2021 Endpoints News 20 Under Forty Biopharma leaders. Sean serves as a board member for the Oregon Bioscience Association, the Oregon Translational Research and Development Institute, and Life Science Washington.
Recent Announcements

For a full list of our most recent announcements, please visit abscent.com/news.
July 7, 2021
Absci Strengthens Executive Leadership Team with Strategic Hires to Support Business Growth

June 30, 2021
Absci Announces Filing of Registration Statement for Proposed Initial Public Offering

June 14, 2021
Absci Announces Acquisition of Target Discovery Company Totient

March 23, 2021
Absci Announces Completion of $125 Million Crossover Financing to Advance AI-Powered Synthetic Biology Drug Creation Platform

January 12, 2021
Absci Announces Acquisition of Deep Learning Company Denovium
Recent News Coverage

For a full list of our most recent announcements, please visit absci.com/news.
Absci Acquires Cell Therapy Company Totient

Bacterial Platforms Can Rival Mammalian Platforms

The 20(+1) under 40: Inside the next generation of biotech leaders

Absci secures $125M in financing

Synthetic biology startup Absci raises $65M to expand ‘Protein Printing’ tech
Brand Assets

Download
logo | logo symbol
headshot 1 | headshot 2

Contact Us

For media inquiries, please reach out to us at press@absci.com.